Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100042/S038

APTIMA HPV ASSAY

Gen-Probe Incorporated · Decision date Feb 3, 2026

FDA DECISIONP100042/S038

What did the FDA approve?

FDA records P100042/S038 as a supplement to PMA P100042, with the supplement type “Panel Track”. The recorded decision is approval, dated Feb 3, 2026.

FDA approval order statement

The Aptima HPV Assay is an in vitro nucleic acid amplification test for the qualitative detection of E6/E7 viral messenger RNA (mRNA) from 14 high-risk types of human papillomavirus (HPV) in cervical specimens. The high-risk HPV types detected by the assay include: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The Aptima HPV Assay does not differentiate between the 14 high-risk types. Cervical specimens in ThinPrep Pap Test vials containing PreservCyt Solution and collected with broom-type or cytobrush/spatula collection devices* may be tested with the Aptima HPV Assay. The assay is used with the Tigris DTS System or the Panther System.The Aptima HPV Assay is indicated for use for routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (adjunctive screening) with cytology, and HPV primary screening of women to assess the risk for cervical pre-cancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors.Primary HPV screening with the Aptima HPV Assay has only been validated on the Panther System.
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Microbiology
Decision date
Feb 3, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P100042/S038
Regulatory pathway
PMA supplement
Product code
OYB
Decision code
APPR
Decision date
Feb 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Kit, rna detection, human papillomavirus.

Product code
OYB
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P100042/S038 received

    Application receipt date recorded by FDA.

  2. P100042/S039 · Related supplement

    Aptima HPV Assay 250T (Panther) Box 1; Aptima HPV Assay 250T (Panther) Box 2; Aptima HPV Assay Calibrators; Aptima HPV A

  3. P100042/S038 · FDA decision

    Panel Track

Timeline entries are records held by MedtechLedger for P100042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100042

Product / regulatory recordCompanyPathwayDecision dateSource
Gen-Probe IncorporatedPMA supplementOct 7, 2025FDA

Explore the linked device profile

Other records with product code OYB

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Gen-Probe Incorporated

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
10210 Genetic Center Dr., San Diego, CA, 92121

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records